Jakob Dupont

Jakob Dupont, MD MA, is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as a Member of the Board of Directors at Bolt Biotherapeutics, Avenzo Therapeutics, and Pyxis Oncology, while also holding the position of Executive Partner at Sofinnova Investments. With extensive experience in research and development, Dupont has been a consultant at Atara Biotherapeutics and Gossamer Bio, and played a key role in the historic approval of EBVallo, the first allogeneic T cell therapy. Educational credentials include a Doctor of Medicine from Joan & Sanford I. Weill Medical College of Cornell University, a Master of Arts in Philosophy from New York University, and a Bachelor of Arts in Philosophy from Vassar College.